インテグリン阻害剤：市場規模、標的人口、競合情勢、市場予測-2034年

当レポートでは、主要7ヶ国におけるインテグリン阻害剤市場について調査し、市場の概要とともに、疫学、患者動向、新たな治療法、2034年までの市場規模予測、および医療のアンメットニーズなどを提供しています。

目次

第1章 重要な洞察

第2章 レポートのイントロダクション

第3章 インテグリン阻害剤のエグゼクティブサマリー

第4章 主要な出来事

第5章 インテグリン阻害剤市場概要

• インテグリン阻害剤の市場シェア（%）分布、治療法別、2023年
• インテグリン阻害剤の市場シェア（%）分布、治療法別、2034年

第6章 背景と概要

第7章 標的人口

第8章 インテグリン阻害剤の上市済み薬剤

第9章 インテグリン阻害剤の新薬

第10章 インテグリン阻害剤：主要7ヶ国分析

• 主な調査結果
• 市場の見通し
• 主要な市場予測の前提条件
• 主要7ヶ国におけるインテグリン阻害剤の総市場規模
• 米国市場
• EU4ヶ国と英国市場
• 日本市場

第11章 アンメットニーズ

第12章 SWOT分析

第13章 KOLの見解

第14章 市場アクセスと償還

• 米国
• EU4ヶ国と英国
• 日本

第15章 付録

第16章 DelveInsightのサービス内容

第17章 免責事項

第18章 DelveInsightについて

List of Tables

• Table 1: Target Population in the 7MM (2020-2034)
• Table 2: Marketed Drug Key cross
• Table 3: Product 1, Clinical Trial Description, 2024
• Table 4: Product 2, Clinical Trial Description, 2024
• Table 5: Emerging Drug Key cross
• Table 6: Product 1, Clinical Trial Description, 2024
• Table 7: Product 2, Clinical Trial Description, 2024
• Table 8: Total Anti-integrin Agents Market Size in the 7MM (2020-2034)
• Table 9: Anti-integrin Agents Market Size by Therapies in the 7MM (2020-2034)
• Table 10: Anti-integrin Agents Market Size by Indication in the 7MM (2020-2034)
• Table 11: Total Anti-integrin Agents Market Size in the United States (2020-2034)
• Table 12: Anti-integrin Agents Market Size by Therapies in the United States (2020-2034)
• Table 13: Total Anti-integrin Agents Market Size in EU4 and the UK (2020-2034)
• Table 14: Anti-integrin Agents Market Size by Therapies in EU4 and the UK (2020-2034)
• Table 15: Total Anti-integrin Agents Market Size in Japan (2020-2034)
• Table 16: Anti-integrin Agents Market Size by Therapies in Japan (2020-2034)

List of Figures

• Figure 1: Target Population in the 7MM (2020-2034)
• Figure 2: Total Anti-integrin Agents Market Size in the 7MM (2020-2034)
• Figure 3: Anti-integrin Agents Market Size by Therapies in the 7MM (2020-2034)
• Figure 4: Anti-integrin Agents Market Size by Indication in the 7MM (2020-2034)
• Figure 5: Total Anti-integrin Agents Market Size in the United States (2020-2034)
• Figure 6: Anti-integrin Agents Market Size by Therapies in the United States (2020-2034)
• Figure 7: Total Anti-integrin Agents Market Size in EU4 and the UK (2020-2034)
• Figure 8: Anti-integrin Agents Market Size by Therapies in EU4 and the UK (2020-2034)
• Figure 9: Total Anti-integrin Agents Market Size in Japan (2020-2034)
• Figure 10: Anti-integrin Agents Market Size by Therapies in Japan (2020-2034)

DelveInsight's "Anti-integrin Agents Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report delivers an in-depth understanding of Anti-integrin Agents, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

The Anti-integrin Agents market report provides insights around existing treatment practices in patients with Anti-integrin Agents, approved (if any) and emerging Anti-integrin Agents, market share of individual therapies, patient pool eligible for treatment with Anti-integrin Agents, along with current and forecasted 7MM Anti-integrin Agents market size from 2020-2034 by therapies and by indication. The report also covers current unmet needs and challenges while incorporating new classes in treatment paradigm, variations in accessibility and acceptability of new Anti-integrin Agents in different geographies, along with insights on Anti-integrin Agents pricing reimbursements to curate the best opportunities and assess the market's potential.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain), and the UK
• Japan

Study Period: 2020-2034

Anti-integrin Agents Overview

This segment will provide detailed information beginning with the inhibitor journey from discovery of the mutation or protein expression to its entry into clinical development followed by its upcoming commercial potential. This segment will dive into the different indications for which the inhibitor is being developed for, which would further give insights on the potential addressable patient population. Moreover, this segment will also give a brief overview around the existing treatment paradigm of the target indications.

Anti-integrin Agents in Clinical Practice

This section will give in depth information about the existing local and systemic options in the current treatment paradigm of all the potential indications, in which most of the pharmaceutical companies are actively evaluating their inhibitors. Potential of the emerging Anti-integrin Agents in changing the current clinical practice guidelines is crucial to analyze especially when it comes to real world scenario.

It will also include the relevance and importance of incorporation of biomarker testing at varying stages of the disease. It is also important to understand that implementing such tests in routine clinical practice is not uniform in different countries due to issues such as cost, accessibility, reimbursement and non-recommendation in guidelines.

Anti-integrin Agents Drug Chapters

The drug chapter segment of the Anti-integrin Agents report encloses a detailed analysis of marketed therapies and late-stage (Phase III and Phase II) therapies. It also helps understand the Anti-integrin Agents clinical trial details, pharmacological action, agreements and collaborations related to Anti-integrin Agents, their approval timelines, patent details, advantages and disadvantages, latest news and press releases.

Anti-integrin Agents Marketed Drugs

The Anti-integrin Agents marketed drug section will provide detailed drug profiles of already approved therapies. Information around clinical development activities, launch timing, regulatory milestones along with safety and efficacy data of the therapy will be included.

Anti-integrin Agents Emerging Drugs

Apart from a comprehensive Anti-integrin Agents competitive landscape in tabular form, the emerging KRAS Inhibitor chapters provides the product details and other development activities of the emerging Anti-integrin Agents under the late and mid-stage of clinical development for various indications.

Note: Detailed list will be provided in the final report.

Drug Class Insights

The Drug Class Insights section will provide comprehensive information on Anti-integrin Agents as a class. This will include a broad overview of the class and its role in treating specific conditions. Insights may cover the historical clinical development of Anti-integrin Agents, their mechanism of action, their subtypes and future commercial prospects. Additionally, the section will provide detailed information about current trends, challenges, and future prospects for this class of drugs.

Anti-integrin Agents Market Outlook

This section will include details on changing Anti-integrin Agents market dynamics post initiation of clinical development activities of the inhibitor. It will also provide a detailed summary and comparison of all the therapies being developed by leading players in this space. This section will highlight the advantages of one therapy over the other after assessment based on parameters such as data availability in the form of safety and efficacy, number of patients enrolled in each trial, and trial's inclusion criteria. There will be a Key focus on the importance of development and need for the commercial success of these targeted therapies to achieve treatment goals that physicians and patients are looking for. It will also sum up all the early stage players active in this space.

Anti-integrin Agents Drugs Uptake

This section focuses on the uptake rate of potential Anti-integrin Agents already launched and expected to be launched in the market during 2020-2034, which depends on the competitive landscape, safety, efficacy data, and order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

Anti-integrin Agents Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III and Phase II stages. It also analyzes key players involved in developing targeted therapeutics.

Anti-integrin Agents Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Anti-integrin Agents.

KOL Views

To keep up with current and future market trends, we incorporate Key physicians, Therapy Area Researcher's, and other Industry Experts' opinions working in the domain through primary research to fill in the data gaps and validate our secondary research. 25+ Key Opinion Leaders (KOLs) were contacted for insights on Anti-integrin Agents' incorporation in the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along with challenges related to accessibility.

Qualitative Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Analyst views. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the analyst's discretion and assessment of the cost analysis and existing and evolving treatment landscape.

Market Access and Reimbursement

This section will include insights around the standard HTA pricing, recent reformations in 2024 and modifications in reimbursement process in the 7MM. For example, In the United States, a multi payer model exists when it comes to drug pricing regime, which is currently undergoing significant changes, with recent federal legislation, such as the Prescription Drug Pricing Reform provisions of the Inflation Reduction Act, significantly altering the pricing regime under certain federal programs. Whereas in Germany, the market access differs from the systems followed in many other countries as no pricing and reimbursement approval is required during launch of a new therapy.

Moreover, this section will also provide details on reimbursement of approved therapy, if any.

Scope of the Report:

• The report covers a segment of key events, an executive summary, target patient pool, epidemiology and market forecasts, information around patient journey and varying biomarker testing rates
• Additionally, an all-inclusive account of the current and emerging therapies drug chapters, insights on Anti-integrin Agents addressable patient pool
• A detailed review of the Anti-integrin Agents market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, and treatment preferences that help in shaping and driving the 7MM Anti-integrin Agents market.
• Market Size of Inhibitors by therapies and indication will be provided

Anti-integrin Agents Report Key Strengths

• 11 Years Anti-integrin Agents Market Forecast
• The 7MM Coverage
• Anti-integrin Agents Competitive Landscape of current and emerging therapies
• Anti-integrin Agents Total Addressable patient population
• Drugs Uptake and Key Market Forecast Assumptions
• Approved and Emerging therapy Profiles
• Physician's perspectives/KOL opinions
• Biomarker testing and Patient journey
• Qualitative Analysis (SWOT and Analyst Views)
• Anti-integrin Agents Market Size by therapy and indication
• Existing and Future Market Opportunity
• Unmet Needs

FAQs

• What was the Anti-integrin Agents total market size, the market size by therapies, market share (%) distribution in 2020, and what would it look like by 2034? What are the contributing factors for Anti-integrin Agents market growth?
• Which KRAS Inhibitor is going to be the largest contributor by 2034?
• What is the market access and reimbursement scenario of Anti-integrin Agents?
• What are the pricing variations among different geographies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Anti-integrin Agents Market.
• Understand the existing Anti-integrin Agents market opportunities and future trends in varying geographies
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility and acceptability of emerging treatment options along with unmet need of current therapies
• Details on report methodology, top indications covered, market assumptions, patient journey and KOLs to strengthen the pharmaceutical companies' development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Anti-integrin Agents

4. Key Events

5. Anti-integrin Agents Market Overview At A Glance

• 5.1. Market Share (%) Distribution of Anti-integrin Agents By Therapy in 2023
• 5.2. Market Share (%) Distribution of Anti-integrin Agents By Therapy in 2034

6. Background And Overview

7. Target Population

8. Anti-integrin Agents Marketed Drugs

• 8.1. Key Competitors
• 8.2. Company 1: Product 1
  • 8.2.1. Product Description
  • 8.2.2. Regulatory Milestones
  • 8.2.3. Other Developmental Activities
  • 8.2.4. Ongoing Clinical Development
  • 8.2.5. Safety and Efficacy
• 8.3. Company 2: Product 2
  • 8.3.1. Product Description
  • 8.3.2. Regulatory Milestones
  • 8.3.3. Other Developmental Activities
  • 8.3.4. Ongoing Clinical Development
  • 8.3.5. Safety and Efficacy
• List to be continued…

9. Anti-integrin Agents Emerging Drugs

• 9.1. Key Competitors
• 9.2. Company 1: Product 1
  • 9.2.1. Product Description
  • 9.2.2. Other Development Activities
  • 9.2.3. Clinical Development
    • 9.2.3.1. Clinical Trials Information
  • 9.2.4. Safety and Efficacy
• 9.3. Company 2: Product 2
  • 9.3.1. Product Description
  • 9.3.2. Other Development Activities
  • 9.3.3. Clinical Development
    • 9.3.3.1. Clinical Trials Information
  • 9.3.4. Safety and Efficacy
• List to be continued…

10. Anti-integrin Agents: The 7MM Analysis

• 10.1. Key Findings
• 10.2. Market Outlook
• 10.3. Key Market Forecast Assumptions
• 10.4. Total Market Size of Anti-integrin Agents in the 7MM
  • 10.4.1. Market Size of Anti-integrin Agents By Therapies In the 7MM
  • 10.4.2. Market Size of Anti-integrin Agents By Indication In the 7MM
• 10.6. United States Market
  • 10.6.1. Total Market Size of Anti-integrin Agents in the United States
  • 10.6.2. Market Size of Anti-integrin Agents By Therapies in the United States
• 10.7. EU4 and the UK Market
  • 10.7.1. Total Market Size of Anti-integrin Agents in EU4 and the UK
  • 10.7.2. Market Size of Anti-integrin Agents By Therapies in EU4 and the UK
• 10.8. Japan Market
  • 10.8.1. Total Market Size of Anti-integrin Agents in Japan
  • 10.8.2. Market Size of Anti-integrin Agents By Therapies in Japan

11. Unmet Needs

12. SWOT Analysis

13. KOL Views

14. Market Access and Reimbursement

• 14.1. United States
  • 14.1.1. Centre for Medicare & Medicaid Services (CMS)
• 14.2. EU4 and the UK
  • 14.2.1. Germany
  • 14.2.2. France
  • 14.2.3. Italy
  • 14.2.4. Spain
  • 14.2.5. United Kingdom
• 14.3. Japan
  • 14.3.1. MHLW

15. Appendix

• 15.1. Bibliography
• 15.2. Report Methodology

16. Delveinsight Capabilities

17. Disclaimer

18. About DelveInsight